Alzheimer's trial closure impacts IXICO
Ixico
8.73p
09:45 15/11/24
-0.26%
-0.02p
Digital technologies company IXICO has received notification from one of its pharmaceutical clients of its decision to stop the screening, randomisation and dosing in a Phase II/III clinical study in Alzheimer's disease in which IXICO is providing specialist imaging clinical trial services, it announced on Tuesday.
FTSE AIM All-Share
728.67
15:45 15/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
-2.70%
-535.19